¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¹ßÇ¥ÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ

Æ÷½ºÅÍ À¯ÀÇ»çÇ×

9¿ù 25ÀÏ(¸ñ) ¿ÀÀü 9½Ã ÀÌÀü±îÁö Æ÷½ºÅ͸¦ ºÎÂøÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
¿ÀÀü 9½ÃºÎÅÍ "ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó" ½É»ç°¡ ½ÃÀ۵˴ϴÙ.

1. Å© ±â : 63.6cm(°¡·Î) X 93.6cm(¼¼·Î)
2. ¼³Ä¡¹æ¹ý : Final ÇÁ·Î±×·¥Áö¿¡ °ÔÀçµÈ ÃÖÁ¾ Æ÷½ºÅÍ ¹øÈ£¸¦ ¹Ýµå½Ã È®ÀÎÇÑ ÈÄ,
        ÇØ´ç Æ÷½ºÅÍ ÆdzÚÀÇ ÇÏ´Ü°ú »ó´ÜÀ» ¸ÂÃß¾î ºÎÂø ºÎÂøÀç·á´Â °³º°Áغñ
3. Àü½Ã±â°£ : 2008³â 9¿ù 25ÀÏ(¸ñ) ¿ÀÀü 9½Ã ~ 27ÀÏ(Åä) ¿ÀÀü 11½Ã

27ÀÏ(Åä) ¿ÀÀü 11½ÃºÎÅÍ Æ÷½ºÅÍ ÆdzÚÀÌ Ã¶¼ö µÇ¿À´Ï ¿ÀÀü 10½Ã~11½Ã »çÀÌ¿¡ Æ÷½ºÅ͸¦ Å»ÂøÇϽñ⠹ٶø´Ï´Ù.

Æ÷½ºÅÍ - Àüü   /    ¸ðüžÆÀÇÇР  /    »ý½Ä³»ºÐºñÇР  /    ºÎÀÎÁ¾¾çÇР  /    ÀϹݺÎÀΰúÇÐ

[ Æ÷½ºÅÍ - ºÎÀÎÁ¾¾çÇÐ ]

Exhibition Hall B
¹øÈ£ ¼º¸í ¼Ò¼Ó Á¦¸ñ
GO1 ¼ÛÀ翬 °¡Å縯ÀÇ´ë ÀڱðæºÎ¾Ï¿¡¼­ MIS type II ¼ö¿ëüÀÇ ¹ßÇö°ú MIS¿¡ ÀÇÇÑ Áõ½Ä¾ïÁ¦È¿°ú
GO2 Á¶±ÝÁØ °í·ÁÀÇ´ë Expression of MMP-2, VEGF, and resistin in hydatiditorm mole.
GO3 Á¤¿ë¿í ¿¬¼¼ÀÇ´ë Human Leukocyte Antigen (HLA)-A2 expression in patients with ovarian cancer: Does it have prognostic relevance to ovarian cancer?
GO4 ¹Ú¿µÇÑ ÇѸ²ÀÇ´ë Ç÷°ü³»ÇǼºÀåÀÎÀÚÀÇ ºÎÀÎ¾Ï ¼¼Æ÷¿¡ ´ëÇÑ ¿µÇâ
GO5 ÀÌÀ¯°æ ¼­¿ïÀÇ´ë Bcl-3 as a carcinogenic factor in endometrial cancer I
GO6 Á¶ÇѺ° ¿¬¼¼ÀÇ´ë Lipocalin2 as a diagnostic and prognostic biomarker for epithelial ovarian cancer
GO7 ÇÑÁöÇý ¼­¿ïÀÇ´ë Prognostic significance of CA 125 response during neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer
GO8 °­¿ì´ë Àü³²ÀÇ´ë Distribution of human papillomavirus genotypes in women with cervical intraepitheial neoplasia and cancer
GO9 ±¸ÃµÈ¸ °¡ÃµÀÇ´ë Radiotherapy or chemoradiotherapy in the adjuvant treatment of early stage cervical cancer: survival and prognostic factors
GO10 ±èÈñ½Â ¼­¿ïÀÇ´ë Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in patients with intermediate-or high risk endometrioid cancer
GO11 Àü°æÈÆ Æ÷õÁß¹®ÀÇ´ë Additional three cycle of paclitaxel-carboplain as Consolidation therapy in patients with advanced epithelial ovarian cancer
GO12 ÀÌÀ¯°æ ¼­¿ïÀÇ´ë Treatment option in early cervical cancers: radical trachelectomy with pelvic lymphadenectomy as a treatment
GO13 ±èÁ¤½Ä ¼øõÇâÀÇ´ë Comparative study for Laparoscopic surgery with Abdominal operation in patients with Endometrial cancer
GO14 ±èÁ¤½Ä ¼øõÇâÀÇ´ë ÀڱðæºÎ¾ÏÀÇ ¼ö¼úÀû Æò°¡¿¡ ´ëÇÑ º¹°­°æÇÏ ±ÙÄ¡ÀÚ±ÃÀýÁ¦¼ú°ú °íÀüÀû ±ÙÄ¡ÀÚ±ÃÀýÁ¦¼úÀÇ ºñ±³
GO15 ±èÁ¤½Ä ¼øõÇâÀÇ´ë ÀڱðæºÎ¾Ï¿¡¼­ º¹°­°æÇÏ ½Å°æ º¸ÀüÀû ±ÙÄ¡ÀÚ±ÃÀýÁ¦¼ú(Laparoscopic nerve sparing radical hysterectomy)ÀÇ ÀÓ»óÀû °íÂû
GO16 È«Àç½Ä °üµ¿ÀÇ´ë The outcome of laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer
GO17 È«´ë±â °æºÏÀÇ´ë ³­¼Ò¾ÏÀÇ ÀÌÂ÷ Ã߽üö¼ú½Ã º¹°­°æ ¼ö¼ú°ú °³º¹¼ö¼ú°úÀÇ ºñ±³
GO18 Çö¹Î°æ ¿ï»êÀÇ´ë Laparoscopic transpertioneal pelvic and paraaortic lymphadenectomy in gynecologic malignancies; analysis of 520 patients at single institution, 1997-2006
GO19 À±¼®±Ù °üµ¿ÀÇ´ë Laparoscopic-assisted surgical staging in the management of endometrial cancer
GO20 °­¿ì´ë Àü³²ÀÇ´ë Is lymphadenectomy necessary for low-risk endometrial cancer on preoperative and intraoperative assessment?
GO21 ±è¹Ì°æ ¼­¿ïÀÇ´ë Management of retroperitoneal lymph nodes in advanced ovarian cancer
GO22 ±è±âµ¿ ¿øÀڷº´¿ø The diagnostic role of parametrectomy in surgery of cervical cancer
GO23 ÁÖ¿ø´ö ¿ï»êÀÇ´ë Four cases of nerve-sparing radical hysterectomy according to Dr. Shingo Fujii's style
GO24 ÇѼÛÀÌ °í·ÁÀÇ´ë ¿ø¹ß¼º ³­°ü¾Ï 10¿¹¿¡ ´ëÇÑ °íÂû
GO25 À§Áö¼± °¡Å縯ÀÇ´ë Ovarian malignancy in pregnancy: Experience for 17 years
GO26 ÇÑÁöÇý ¼­¿ïÀÇ´ë Clinical features of primary carcinoma of the fallopian tube
GO27 Àü°æÈÆ Æ÷õÁß¹®ÀÇ´ë Clinical study of clear cell carcinoma of the ovary
GO28 ±èöÁß ¼º±Õ°üÀÇ´ë The clinical characteristics and treatment results in the patients with clear cell carcinoma of the ovary
GO29 Â÷°æÈñ ¿ï»êÀÇ´ë Analysis of prognostic factors for high risk histologic types of endometrial cancer
GO30 ¼ÛÀ翬 °í·ÁÀÇ´ë Predictive factors for positive margin after conization
GO31 È«Àç½Ä °üµ¿ÀÇ´ë The efficacy of cone biopsy on patients with carcinoma in situ and microinvasive squamous cell carcinoma of uterine cervix
GO32 È«Àç½Ä °üµ¿ÀÇ´ë Prevalence of endometrial carcinoma after hysterectomy for atypical endometrial hyperplasia diagnosed on endometrial biopsy
GO33 ÃÖÀÏÁ¤ µ¿¾ÆÀÇ´ë ÀڱðæºÎ CIN 3 ȯÀÚ¿¡¼­ Àڱà º¸Á¸À» ¸ñÀûÀ¸·Î ½ÃÇàÇÑ ÀڱðæºÎ ¿øÃßÀýÁ¦¼úÀÇ È¿¿ë¼º
GO34 ÀÓ°æÁø ¿¬¼¼ÀÇ´ë Deep vein thrombosis with ovarian cancer: The incidence of deep vein thrombosis and survival
GO35 ¹Ú¿ëÁÖ ÀÎÁ¦ÀÇ´ë ÀڱðæºÎ¾Ï ȯÀÚ¿¡¼­ Ä¡·áÀü Ç÷»ö¼Ò ³óµµ°¡ ÀÓ»óº´¸®ÇÐÀû ¿¹ÈÄÀÎÀÚ ¹× Ä¡·á°á°ú¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÑ ¿¬±¸
GO36 Á¤ÇýÀÎ ºÎ»êÀÇ´ë A case of ovarian mucinous cystadenofibroma with minor sex-cord elements
GO37 ±èÁøÈÖ °¡Å縯ÀÇ´ë A case of malignant transformation of mitotically active leiomyoma after total hysterectomy
GO38 ¹ÚÁö±Ç °æ»óÀÇ´ë Endometrial carcinoma in a patient having 45,X Turner syndrome with gonadal mosaicism
GO39 ¼Ûµ¿È­ °æÈñÀÇ´ë Intracavitary cardiac metastasis arising from squamous cell carcinoma of the uterine cervix with pulmonary embolism
GO40 ȲÁ¾ÇÏ °í·ÁÀÇ´ë Pseudomyxoma peritonei associated with a borderline mucinous tumor in a mature cystic teratoma of the ovary
GO41 ±èÁö¿ø °í·ÁÀÇ´ë Mullerian adenosarcoma of the uterus with sarcomatous overgrowth : multiple recurrence within 1 months during radiation therapy
GO42 ÀÌÅÂÈ­ °í½ÅÀÇ´ë Malignant fibrous histiocytoma of the vagina and vulva
GO43 Á¤Àº¿µ ¼øõÇâÀÇ´ë Æ󵿸ƻöÀüÁõ°ú µ¿¹ÝµÈ ¾ç¼º Schwannoma 1¿¹
GO44 ±èÁ¤½Ä ¼øõÇâÀÇ´ë Ovarian clear cell carcinoma producing human chorionic gonadotrophin
GO45 À̸¶¸®¾Æ ¿¬¼¼ÀÇ´ë A case of transitional cell carcinoma of the renal pelvis with ovarian metastasis
GO46 ±ÇÇý¼º ÀÎÁ¦ÀÇ´ë Ç÷Àü »öÀüÁõÀ» À¯¹ßÇÑ Àڱûù±ÙÁõ 1¿¹
GO47 ±èÇöÁ¤ ÁÁÀº¹®È­º´¿ø A case of adenoma malignum diagnosed before surgical treatment
GO48 ±èÇöÁ¤ ÁÁÀº¹®È­º´¿ø A case of diffuse laminar endocervical glandular hyperplasia
GO49 ±è¿µÀç ÇѾçÀÇ´ë Adenoid basal carcinoma of the uterine cervix: Report of two cases